[Procedure in case of suspected mycobacterial infection of lymph nodes of the neck. 2. Therapy].
In the treatment of tuberculosis the patients normally receive a two month daily treatment with Isoniazid, Rifampicin, Pyrazinamid and Ethambutol, followed by a daily treatment with Isoniazid and Rifampicin for four month. The atypical mycobacterial infections can be addressed as a local infection and are amendable to surgical therapy, eventually followed by a daily treatment with antibiotics for four to twelve weeks. In Germany it is obligatory to inform the local public health department about typical mycobacterial infections. Hygiene procedures following German law are discussed in this review.
Göpel
B
B
Universitäts-Hals-Nasen-Ohrenklinik, Universitätsklinikum Mannheim, Theodor-Kutzer-Ufer 1-3, 68135 Mannheim, Germany.
Götte
K
K
D000328:Adult; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000627:therapeutic use; D000904:Antibiotics, Antitubercular / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D000995:Antitubercular Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D018563:Disease Notification / Q000331:legislation & jurisprudence; D004359:Drug Therapy, Combination; D004977:Ethambutol / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D005260:Female; D005858:Germany; D006801:Humans; D016867:Immunocompromised Host; D007538:Isoniazid / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D008297:Male; D009164:Mycobacterium Infections / Q000188:drug therapy* / Q000517:prevention & control; D009165:Mycobacterium Infections, Nontuberculous / Q000188:drug therapy / Q000517:prevention & control; D010356:Patient Isolation; D011718:Pyrazinamide / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D012293:Rifampin / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D013307:Streptomycin / Q000009:adverse effects / Q000627:therapeutic use; D013997:Time Factors; D014388:Tuberculosis, Lymph Node / Q000188:drug therapy* / Q000517:prevention & control
D000900:Anti-Bacterial Agents; D000904:Antibiotics, Antitubercular; D000995:Antitubercular Agents; D011718:Pyrazinamide; D004977:Ethambutol; D007538:Isoniazid; D012293:Rifampin; D013307:Streptomycin